Reviewed profile

food and beverage brand · public preview

Zepbound

Retail brand

Public category
Retail brand
Brand tier
mainstream brand
Is this your company?Claim Zepbound to get found by buyers, add products and certifications, correct your details, and be eligible when Talio’s AI recommends suppliers.Let our AI make the introductionGet a warm, researched intro to Zepbound — no cold outreach.
Report a changeLog in for full recordLast reviewed 28 Mar 2026 · public preview data

Overview

What Zepbound covers.

Zepbound is a prescription medication developed by Eli Lilly and Company, approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It contains the active ingredient tirzepatide, which functions as a dual GIP and GLP-1 receptor agonist. The product is targeted toward individuals seeking pharmacological intervention for significant, sustained weight loss. Zepbound is positioned within the pharmaceutical sector as a leading treatment option for chronic weight management.

  • Positioned as a mainstream brand.

FAQ

Questions this page answers.

What does Zepbound do?

Zepbound is a food and beverage brand, tracked in Talio's food and beverage intelligence platform.

Is this the full Talio record?

No. This page is a public preview; proprietary metrics and workflow features remain inside authenticated Talio.

Own this company?

Get found by buyers — and the AI that recommends suppliers.

Claim this profile to appear in buyer searches, add your products and certifications, correct outdated details, and stay eligible when Talio's AI recommends suppliers.

Claiming grants reviewed submission rights only — not direct editing, suppression, or ownership of Talio-derived intelligence. Verification required.

Claim this pageLog in for full recordReport a change

Public preview data only · proprietary metrics remain in authenticated Talio.